Endo International PLC to Post Q1 2017 Earnings of $1.63 Per Share, Oppenheimer Holdings Forecasts (ENDP)
Endo International PLC (NASDAQ:ENDP) – Equities research analysts at Oppenheimer Holdings raised their Q1 2017 earnings per share (EPS) estimates for shares of Endo International PLC in a note issued to investors on Tuesday. Oppenheimer Holdings analyst M. Ho now anticipates that the firm will post earnings per share of $1.63 for the quarter, up from their previous forecast of $1.61. Oppenheimer Holdings has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for Endo International PLC’s Q2 2017 earnings at $1.26 EPS, Q3 2017 earnings at $1.12 EPS, Q4 2017 earnings at $1.06 EPS and FY2017 earnings at $5.07 EPS.
Endo International PLC (NASDAQ:ENDP) last posted its quarterly earnings data on Tuesday, November 8th. The company reported $1.01 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.20. Endo International PLC had a negative net margin of 3.32% and a positive return on equity of 15.95%. The business earned $894.30 million during the quarter, compared to analyst estimates of $862.47 million. During the same quarter last year, the firm posted $1.02 earnings per share. The business’s revenue for the quarter was up 18.6% compared to the same quarter last year.
Other research analysts have also issued reports about the stock. Mizuho upgraded shares of Endo International PLC from a “neutral” rating to a “buy” rating and upped their target price for the company from $16.00 to $29.00 in a report on Friday, August 12th. Northland Securities upgraded shares of Endo International PLC from a “market perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a report on Thursday, September 29th. Vetr lowered shares of Endo International PLC from a “hold” rating to a “strong sell” rating and set a $18.21 target price on the stock. in a report on Tuesday, August 9th. Piper Jaffray Cos. restated a “neutral” rating and issued a $19.00 target price on shares of Endo International PLC in a report on Tuesday, September 27th. Finally, Citigroup Inc. reduced their target price on shares of Endo International PLC from $40.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, September 16th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $33.52.
Endo International PLC (NASDAQ:ENDP) opened at 17.58 on Thursday. The stock’s market cap is $3.92 billion. The stock has a 50 day moving average of $19.61 and a 200 day moving average of $19.06. Endo International PLC has a 1-year low of $12.56 and a 1-year high of $63.71.
Institutional investors have recently made changes to their positions in the company. Meeder Asset Management Inc. purchased a new position in shares of Endo International PLC during the first quarter valued at about $139,000. Acrospire Investment Management LLC boosted its stake in Endo International PLC by 139.3% in the third quarter. Acrospire Investment Management LLC now owns 7,897 shares of the company’s stock worth $159,000 after buying an additional 4,597 shares during the last quarter. LS Investment Advisors LLC boosted its stake in Endo International PLC by 152.3% in the second quarter. LS Investment Advisors LLC now owns 13,661 shares of the company’s stock worth $213,000 after buying an additional 8,247 shares during the last quarter. Icon Advisers Inc. Co. bought a new stake in Endo International PLC during the second quarter worth about $218,000. Finally, IFP Advisors Inc boosted its stake in Endo International PLC by 103,542.9% in the second quarter. IFP Advisors Inc now owns 14,510 shares of the company’s stock worth $226,000 after buying an additional 14,496 shares during the last quarter. Hedge funds and other institutional investors own 96.61% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.